123. Liu Y, Gunda V, Zhu X, Xu X, Wu J, Askhatova D, Farokhzad OC, Parangi S, Shi J, Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer, Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7750-5. Full Text

122.  Xue Y, Xu X, Zhang XQ, Farokhzad OC, Langer R. Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles. Proc Natl Acad Sci U S A. (2016) May 2;17;113(20):5552-7. Full Text

121.  Xu X, Wu J, Liu Y, Yu M, Zhao L, Zhu X, Bhasin S, Li Q, Ha E, Shi J, Farokhzad OC. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy. Angew Chem Int Ed Engl. (2016) May 3;[Epub ahead of print]. Full Text

120.  Kamaly N, Fredman G, Fojas JJ, Subramanian M, Choi WI, Zepeda K, Vilos C, Yu M, Gadde S, Wu J, Milton J, Carvalho Leitao R, Rosa Fernandes L, Hasan M, Gao H, Nguyen V, Harris J, Tabas I, Farokhzad OC. Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis. ACS Nano. (2016 ) Apr 28. Full Text

119.  Chung BL, Toth MJ, Kamaly N, Sei YJ, Becraft J, Mulder WJ, Fayad ZA, Farokhzad OC, Kim Y, Langer R. Nanomedicines for Endothelial Disorders. Nano Today (2015) Dec 1; 10(6):759-776. Full Text

118.  Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release, Chem Rev. (2016) Feb 8;[Epub ahead of print]. Full Text

117.  Zhu X, Wu J, Shan W, Tao W, Zhao L, Lim JM, D’Ortenzio M, Karnik R, Huang Y, Shi J, Farokhzad OC. Polymeric Nanoparticles Amenable to Simultaneous Installation of Exterior Targeting and Interior Therapeutic Proteins, Angew Chem Int Ed Engl. (2016) Feb 5;[Epub ahead of print]. Full Text

116.  Miller MA, Gadde S, Pfirschke C, Engblom C, Sprachman MM, Kohler RH, Yang KS, Laughney AM, Wojtkiewicz G, Kamaly N, Bhonagiri S, Pittet MJ, Farokhzad OC, Weissleder R. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle, Sci Transl Med. (2015) Nov 18;7(314):314ra183. Full Text

115.  Miller MA, Zheng YR, Gadde S, Pfirschke C, Zope H, Engblom C, Kohler RH, Iwamoto Y, Yang KS, Askevold B, Kolishetti N, Pittet M, Lippard SJ, Farokhzad OC, Weissleder R., Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug, Nature Commun. (2015) Oct 27;6:8692. Full Text

114.  Yu M, Wu J, Shi J, Farokhzad OC., Nanotechnology for protein delivery: Overview and perspectives, J Control Release (2015) Oct 13; S0168-3659(15)30180-2. Full Text

113.  Farokhzad OC., Nanotechnology: Platelet mimicry, Nature (2015) Oct 1;526(7571):47-8. Full Text

112.  Yameen B, Vilos C, Choi WI, Whyte A, Huang J, Pollit L, Farokhzad OC., Drug Delivery Nanocarriers from a Fully Degradable PEG-Conjugated Polyester with a Reduction-Responsive Backbone, Chemistry (2015) Aug 3;21(32):11325-9. Full Text

111.  Wu J, Zhao L, Xu X, Bertrand N, Choi WI, Yameen B, Shi J, Shah V, Mulvale M, MacLean JL, Farokhzad OC., Hydrophobic Cysteine Poly(disulfide)-based Redox-Hypersensitive Nanoparticle Platform for Cancer Theranostics, Angew Chem Int Ed Engl. (2015) Aug 3;54(32):9218-23. Full Text

110.  Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, Basto PA, Perro M, Vrbanac VD, Tager AM, Shi J, Yethon JA, Farokhzad OC, Langer R, Starnbach MN, von Andrian UH., A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells, Science. (2015) Jun 19;348(6241):aaa8205. Full Text

109.   Zhu X, Xu Y, Solis LM, Tao W, Wang L, Behrens C, Xu X, Zhao L, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J., Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment, Proc Natl Acad Sci U S A. (2015) Jun 23;112(25):7779-84. Full Text

108.   Saw PE, Park J, Lee E, Ahn S, Lee J, Kim H, Kim J, Choi M, Farokhzad OC, Jon S., Effect of PEG pairing on the efficiency of cancer-targeting liposomes, Theranostics. 5(2015) 746-54. Full Text

107.   Pridgen EM, Alexis F, Farokhzad OC., Polymeric nanoparticle drug delivery technologies for oral delivery applications, Expert Opin Drug Deliv. (2015) Sep;12(9):1459-73. Full Text

106.  Gabrielle Fredman, Nazila Kamaly, Stefano Spolitu, Jaclyn Milton, Devram Ghorpade, Raymond Chiasson, George Kuriakose, Mauro Perretti, Omid Farokzhad and Ira Tabas, Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Science Translational Medicine, 7(2015) 275ra20. Full Text

105.  Leoni G, Neumann PA, Kamaly N, Quiros M, Nishio H, Jones HR, Sumagin R, Hilgarth RS, Alam A, Fredman G, Argyris I, Rijcken E, Kusters D, Reutelingsperger C, Perretti M, Parkos CA, Farokhzad OC, Neish AS, Nusrat A. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. Proc Natl Acad Sci U S A, (2015) Mar 2;125(3):1215-27. Full Text

104.  Maldonado RA, LaMothe RA, Ferrari JD, Zhang A, Rossi RJ, Kolte PN, Griset AP, O’Neil C, Altreuter DH, Browning E, Johnston L, Farokhzad OC, Langer R, Scott DW, von Andrian UH, Kishimoto TK. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A, (2015) Jan 13;112(2):E156-65. Full Text

103.  Choi WI, Kamaly N, Riol-Blanco L, Lee IH, Wu J, Swami A, Vilos C, Yameen B, Yu M, Shi J, Tabas I, von Andrian UH, Jon S, Farokhzad OC. A Solvent-Free Thermosponge Nanoparticle Platform for Efficient Delivery of Labile Proteins. Nano Lett, 14(2014):6449-55. Full Text

102. Zhang XQ, Even-Or O, Xu X, van Rosmalen M, Lim L, Gadde S, Farokhzad OC, Fisher EA. Nanoparticles Containing a Liver X Receptor Agonist Inhibit Inflammation and Atherosclerosis. Adv Healthc Mater, (2015) Jan 28;4(2):228-36. Full Text

101. Wu J, Kamaly N, Shi J, Zhao L, Xiao Z, Hollett G, John R, Ray S, Xu X, Zhang X, Kantoff PW, Farokhzad OC. Development of Multinuclear Polymeric Nanoparticles as Robust Protein Nanocarriers. Angew Chem Int Ed Engl, 53(2014) 8975-9. Full Text

100.  Yameen B, Choi WI, Vilos C, Swami A, Shi J, Farokhzad OC. Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release, 190(2014) 485-99. Full Text

99.  Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D, Zhang Y, Liu J, Memarzadeh M, Wu J, Manier S, Shi J, Bertrand N, Lu ZN, Nagano K, Baron R, Sacco A, Roccaro AM, Farokhzad OC, Ghobrial IM. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A, 111(2014) 10287-92. Full Text

98.  Pridgen EM, Alexis F, Farokhzad OC. Polymeric Nanoparticle Technologies for Oral Drug Delivery. Clin Gastroenterol Hepatol, 12(2014) 1605-10. Full Text

97.  Lim JM, Swami A, Gilson LM, Chopra S, Choi S, Wu J, Langer R, Karnik R, Farokhzad OC. Ultra-High Throughput Synthesis of Nanoparticles with Homogeneous Size Distribution Using a Coaxial Turbulent Jet Mixer. ACS Nano, 8(2014) 6056-65. Full Text

96.  Gadde S, Even-Or O, Kamaly N, Hasija A, Gagnon PG, Adusumilli KH, Erakovic A, Pal AK, Zhang XQ, Kolishetti N, Shi J, Fisher EA, Farokhzad OC. Development of Therapeutic Polymeric Nanoparticles for the Resolution of Inflammation. Adv Healthc Mater, 3(2014) 1448-56. Full Text

95.  Shi J, Xu Y, Xu X, Zhu X, Pridgen E, Wu J, Votruba AR, Archana S, Zetter BR, Farokhzad OC. Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing. Nanomedicine, 10(2014) 897-900. Full Text

94.  Ilyinskii PO, Roy CJ, O’Neil CP, Browning EA, Pittet LA, Altreuter DH, Alexis F, Tonti E, Shi J, Basto PA, Iannacone M, Radovic-Moreno AF, Langer RS, Farokhzad OC, von Andrian UH, Johnston LP, Kishimoto TK. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine, 32(2014) 2882-95. Full Text

93.  Gendelman HE, Balogh LP, Bawa R, Bradbury M, Chang EH, Chiu W, Farokhzad O, Foldvari M, Lanza G, Wang K. Fourth annual conference of the american society for nanomedicine. J Neuroimmune Pharmacol, 1(2014) 1-38. Full Text

92.  Wang AZ, Farokhzad OC. Current progress of aptamer-based molecular imaging. Proc Natl Acad Sci U S A, 55(2014) 353-6. Full Text

91.  Kim Y, Lobatto ME, Kawahara T, Lee Chung B, Mieszawska AJ, Sanchez-Gaytan BL, Fay F, Senders ML, Calcagno C, Becraft J, Tun Saung M, Gordon RE, Stroes ES, Ma M, Farokhzad OC, Fayad ZA, Mulder WJ, Langer R. Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proc Natl Acad Sci U S A, 111(2014) 1078-83. Full Text

90.  Pridgen EM, Alexis F, Kuo TT, Levy-Nissenbaum E, Karnik R, Blumberg RS, Langer R, Farokhzad OC. Transepithelial transport of fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med, 5(2013) 213ra167. Full Text

89.  Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev, 66C(2013) 2-25. Full Text

88.  Valencia PM, Pridgen EM, Rhee M, Langer R, Farokhzad OC, Karnik R. Microfluidic Platform for Combinatorial Synthesis and Optimization of Targeted Nanoparticles for Cancer Therapy. ACS Nano, 7(2013) 10671-80. Full Text

87.  Xu X, Xie K, Zhang XQ, Pridgen EM, Park GY, Cui DS, Shi J, Wu J, Kantoff PW, Lippard SJ, Langer R, Walker GC, Farokhzad OC. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci USA, 110(2013) 18638. Full Text

86.  Kim Y, Fay F, Cormode DP, Sanchez-Gaytan BL, Tang J, Hennessy EJ, Ma M, Moore K, Farokhzad OC, Fisher EA, Mulder WJ, Langer R, Fayad ZA. Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano, 7(2013) 9975. Full Text

85.  Lim JM, Bertrand N, Valencia PM, Rhee M, Langer R, Jon S, Farokhzad OC, Karnik R. Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. Nanomedicine, 10(2014) 401-9. Full Text

84.  Mieszawska AJ, Kim Y, Gianella A, van Rooy I, Priem B, Labarre MP, Ozcan C, Cormode DP, Petrov A, Langer R, Farokhzad OC, Fayad ZA, Mulder WJ. Synthesis of Polymer-Lipid Nanoparticles for Image-Guided Delivery of Dual Modality Therapy. Bioconjug Chem, 24(2013) 1429. Full Text

83.  Gianella A, Mieszawska AJ, Hoeben FJ, Janssen HM, Jarzyna PA, Cormode DP, Costa KD, Rao S, Farokhzad OC, Langer R, Fayad ZA, Mulder WJ. Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform. Chem Commun, 49(2013) 9392. Full Text

82.  Johnstone TC, Kulak N, Pridgen EM, Farokhzad OC, Langer R, Lippard SJ. Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano, 7(2013) 5675. Full Text

81.  Kamaly N, Fredman G, Subramanian M, Gadde S, Pesic A, Fayad ZA, Langer R, Tabas I, Farokhzad OC. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A, 10(2013) 6506. Full Text

80.  Prabhakar U, Blakey DC, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P. Challenges and key considerations of the enhanced permeability and retention effect (EPR) for nanomedicine drug delivery in oncology. Cancer Res, 73(2013) 2412. Full Text

79.  Zhao W, Cui CH, Bose S, Guo D, Shen C, Wong WP, Halvorsen K, Farokhzad OC, Teo GS, Phillips JA, Dorfman DM, Karnik R, Karp JM. Bioinspired multivalent DNA network for capture and release of cells. Proc Natl Acad Sci U S A, 109(2012) 19626. Full Text

78.  Salvador-Morales C, Valencia PM, Gao W, Karnik R, Farokhzad OC. Spontaneous Formation of Heterogeneous Patches on Polymer-Lipid Core-Shell Particle Surfaces during Self-Assembly. Small, 9(2013) 511. Full Text

77.  Xiao Z, Ji C, Shi J, Pridgen EM, Frieder J, Wu J, Farokhzad OC. DNA Self-Assembly of Targeted Near-Infrared-Responsive Gold Nanoparticles for Cancer Thermo-Chemotherapy. Angew Chem Int Ed Engl., 51(2012) 11853. Full Text

76.  Valencia PM, Pridgen EM, Perea B, Gadde S, Sweeney C, Kantoff PW, Bander NH, Lippard SJ, Langer R, Karnik R, Farokhzad OC. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond), 5(2013) 687. Full Text

75.  Farokhzad OC. Using ligands to target cancer cells. Clin Adv Hematol Oncol, 8(2012) 543. Full Text

74.  Valencia PM, Farokhzad OC, Karnik R, Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnology, 7(2012) 623. Full Text

73.  Zhang XQ, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC. “Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine”. Advanced Drug Delivery Reviews, 64(2012) 1363. Full Text

72.  Kim Y, Chung BL, Ma M, Mulder WJ, Fayad ZA, Farokhzad OC, Langer R. “Mass Production and Size Control of Lipid-Polymer Hybrid Nanoparticles through Controlled Microvortices”. Nano Letters, 12(2012) 3587. Full Text

71.  Graf N, Bielenberg DR, Kolishetti N, Muus C, Banyard J, Farokhzad OC, Lippard SJ. “a(V)ß(3) Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug”. ACS Nano, 6(2012) 4530. Full Text

70.  Xiao Z, Farokhzad OC. “Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities”. ACS Nano, 6(2012) 3670. Full Text

69.  Mieszawska AJ, Gianella A, Cormode DP, Zhao Y, Meijerink A, Langer R, Farokhzad OC, Fayad ZA, Mulder WJ. . “Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging”. Chem Commun, 48(2012) 5835. Full Text

68.  Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, Lorusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. “Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile”. Science Translational Medicine, 4(2012) 128ra39. Full Text

67.  Radovic-Moreno AF, Lu TK, Puscasu VA, Yoon CJ, Langer R, Farokhzad OC. “Surface Charge-Switching Polymeric Nanoparticles for Bacterial Cell Wall-Targeted Delivery of Antibiotics”. ACS Nano, 6(2012) 4279. Full Text

66.  Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF and Farokhzad OC. “Targeted polymeric therapeutic nanoparticles: design, development and clinical translation”. Chemical Society Reviews, 41 (2012) 2971. Full Text

65.  Xiao Z, Levy-Nissenbaum E, Alexis F, Lupták A, Teply BA, Chan JM, Shi J, Digga E, Cheng J, Langer R and Farokhzad OC. “Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection”. ACS Nano, 6 (2012) 696. Full Text

64.  Chan JM, Rhee JW, Drum CL, Bronson RT, Golomb G, Langer R and Farokhzad OC. “In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles”. Proc Natl Acad Sci U S A, 108 (2012) 19347. Full Text

63.  Wang AZ, Langer R and Farokhzad OC. “Nanoparticle delivery of cancer drugs”. Annual Reviews of Medicine, 63 (2012) 185. Full Text

62.  Shi J, Xiao Z, Kamaly N and Farokhzad OC. “Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation”. Accounts of Chemical Research, 44 (2011) 1123. Full Text

61.  Valencia PM, Hanewich-Hollatz MH, Gao W, Karim F, Langer R, Karnik R and Farokhzad OC. “Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles”. Biomaterials, 32 (2011) 6226. Full Text

60. Rhee M, Valencia PM, Rodriguez MI, Langer R, Farokhzad OC and Karnik R. “Synthesis of Size-Tunable Polymeric Nanoparticles Enabled by 3D Hydrodynamic Flow Focusing in Single-Layer Microchannels”. Advanced Materials, 23 (2011) H79. Full Text

59. Timko BP, Whitehead K, Gao W, Kohane DS, Farokhzad OC, Anderson D, and Langer R. “Advances in Drug Delivery”. Annual Review of Materials Research, 41 (2011) 1. Full Text

58.  Shi JJ, Xiao ZY, Votruba AR, Vilos C and Farokhzad OC. “Differentially Charged Hollow Core/Shell Lipid-Polymer-Lipid Hybrid Nanoparticles for Small Interfering RNA Delivery”. Angewandte Chemie International Edition, 50 (2011) 7027. Full Text

57.  Gao W and Farokhzad OC. “Self-Propelled Microrockets to Capture and Isolate Circulating Tumor Cells (Perspective) “. Angewandte Chemie International Edition, 50 (2011) 7220. Full Text

56.  Dhar S, Kolishetti N, Lippard SJ and Farokhzad OC “Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo”. Proc Natl Acad Sci U S A, 108 (2011) 1850. Full Text

55.  Burgess P, Hutt PB, Farokhzad OC, Langer R and Minick S, Zale S. “On firm ground: IP protection of therapeutic nanoparticles”. Nature Biotechnology, 28 (2010) 1267. Full Text

54.  Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R and Farokhzad OC. “Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy”. Proc Natl Acad Sci U S A, 107 (2010) 17939. Full Text

53.  Shi JJ, Votruba AR, Farokhzad OC and Langer R. “Nanotechnology in drug delivery and tissue engineering: From discovery to applications”. NanoLetters, 10 (2010) 3223. Full Text

52.  Gao W, Langer R, and Farokhzad OC. “Poly(ethylene glycol) with observable shedding”. Angewandte Chemie International Edition, 45 (2010) 6567. Full Text

51.  Wang AZ, Yuet K, Zhang LF, Gu FX, Huynh-Le M, Radovic-Moreno AF, Kantoff PW, Bander NH, Langer R and Farokhzad OC. “ChemoRad nanopartides: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation”. Nanomedicine, 5 (2010) 361. Full Text

50.  Valencia PM, Basto PA, Zhang LF, Rhee M , Langer R, Farokhzad OC and Karnik R. “Single-step assembly of homogenous lipid -polymeric and lipid – quantum dot nanoparticles enabled by microfluidic rapid mixing”. ACS Nano, 3 (2010) 1671. Full Text

49.  Mamo T, Moseman EA, Kolishetti N, Morales CS, Shi J, Kuritzkes DR, Langer R, von Andrian U and Farokhzad OC. “Emerging nanotechnology approaches for HIV/AIDS treatment and prevention”. Nanomedicine, 5 (2010) 269. Full Text

48.  Chan JM, Zhang L,Tong R, Ghosh D, Gao W, Liao G, Yuet KP, Gray D, Rhee J, Cheng J, Golomb G, Libby P, Langer R and Farokhzad OC. “Spatiotemporal controlled delivery of nanoparticles to injured vasculature”.Proc Natl Acad Sci U S A, 107 (2010) 2213. Full Text

47.  Farokhzad OC and Langer R.”Impact of nanotechnology on drug delivery.” ACS Nano, 3 (2009) 16. Full Text

46.  Gu F, Langer R and Farokhzad OC. “Formulation/Preparation of functionalized nanoparticles for in vivo targeted drug delivery.” Methods Mol Biol, 544 (2009) 589. Full Text

45.  Bassett EK, Slocum AH, Masiakos PT, Pryor HI 2nd, Farokhzad OC and Karp JM. “Design of a mechanical clutch-based needle-insertion device.” Proc Natl Acad Sci U S A,106 (2009) 5540. Full Text

44.  Salvador-Morales C, Gao W, Ghatalia P, Murshed F, Aizu W, Langer R and Farokhzad OC. “Multifunctional nanoparticles for prostate cancer therapy.” Expert Rev Anticancer Ther, 9( 2009) 211. Full Text

43.  Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R and Farokhzad OC. “PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery.” Biomaterials, 30 (2009) 1627. Full Text

42.  Salvador-Morales C, Zhang L, Langer R and Farokhzad OC. “Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups.” Biomaterials, 30 (2009) 2231. Full Text

41.  Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, Alexis F, Langer R and Farokhzad OC.”Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform.” ACS Nano, 2 (2008) 1696. Full Text

40.  Alexis F, Basto P, Levy-Nissenbaum E, Radovic-Moreno AF, Zhang L, Pridgen E, Wang AZ, Marein SL, Westerhof K, Molnar LK and Farokhzad OC. “HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.” ChemMedChem, 3 (2008) 1839. Full Text

39.  Dhar S, Gu FX, Langer R, Farokhzad OC and Lippard SJ. “Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.” Proc Natl Acad Sci U S A,105 (2008) 17356. Full Text

38.  Wang AZ, Gu F, Zhang L, Chan JM, Radovic-Moreno A, Shaikh MR and Farokhzad OC. “Biofunctionalized targeted nanoparticles for therapeutic applications.” Expert Opin Biol Ther, 8 (2008) 1063. Full Text

37.  Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R and Farokhzad OC. “Nanotechnology and aptamers: applications in drug delivery.” Trends Biotechnol, 26 (2008) 442. Full Text

36.  Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R and Farokhzad OC. “New frontiers in nanotechnology for cancer treatment.” Urol Oncol, 26 (2008) 74. Full Text

35.  Teply BA, Tong R, Jeong SY, Luther G, Sherifi I, Yim CH, Khademhosseini A, Farokhzad OC, Langer RS and Cheng J. “The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules.” Biomaterials, 29 (2008) 1216. Full Text

34.  Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS and Farokhzad OC. “Nanoparticles in medicine: therapeutic applications and developments.” Clin Pharmacol Ther, 83 (2008) 761. Full Text

33.  Farokhzad OC.”Nanotechnology for drug delivery: the perfect partnership.” Expert Opin Drug Deliv, 5 (2008) 927. Full Text

32.  Alexis F, Pridgen E, Molnar LK and Farokhzad OC.”Factors affecting the clearance and biodistribution of polymeric nanoparticles.” Mol Pharm, 5 (2008) 505. Full Text

31.  Karnik R, Gu F, Basto P, Cannizzaro C, Dean L, Kyei-Manu W, Langer R and Farokhzad OC.”Microfluidic platform for controlled synthesis of polymeric nanoparticles.” Nano Lett, 8 (2008) 2906. Full Text

30.  Wang AZ, Bagalkot V, Vasilliou CC, Gu F, Alexis F, Zhang L, Shaikh M, Yuet K, Cima MJ, Langer R, Kantoff PW, Bander NH, Jon S and Farokhzad OC. “Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.” ChemMedChem, 3 (2008) 1311. Full Text

29.  Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R and Farokhzad OC. “Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.” Proc Natl Acad Sci U S A, 105 (2008) 2586. Full Text

28.  Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R and Langer R. “Nanocarriers as an emerging platform for cancer therapy.” Nat Nanotechnol, 2 (2007) 751. Full Text

27.  Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R and Farokhzad OC. “Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.” Nano Lett, 7 (2007) 3065. Full Text

26.  Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, Jon S, Langer RS and Farokhzad OC. “Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates.” ChemMedChem, 2 (2007) 1268. Full Text

25.  Pridgen EM, Langer R and Farokhzad OC. “Biodegradable, polymeric nanoparticle delivery systems for cancer therapy.” Nanomed, 2 (2007) 669. Full Text

24.  Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R and Farokhzad OC. “Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.” Biomaterials, 28 (2007) 869. Full Text

23.  Park H, Cannizzaro C, Vunjak-Novakovic G, Langer R, Vacanti CA and Farokhzad OC. “Nanofabrication and Microfabrication of Functional Materials for Tissue Engineering.” Tissue Eng, 13 (2007) 1867. Full Text

22.  Farokhzad OC, Dimitrakov JD, Karp JM, Khademhosseini A, Freeman MR and Langer R. “Drug delivery systems in urology–getting smarter.” Urology, 68 (2006) 463. Full Text

21.  Farokhzad OC, Karp JM and Langer R. “Nanoparticle-aptamer bioconjugates for cancer targeting.” Expert Opin Drug Deliv, 3 (2006) 311. Full Text

20.  Bagalkot V, Farokhzad OC, Langer R and Jon S. “An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform.” Angew Chem Int Ed Engl, 45 (2006) 8149. Full Text

19.  Fukuda J, Khademhosseini A, Yeh J, Eng G, Cheng J, Farokhzad OC and Langer R. “Micropatterned cell co-cultures using layer-by-layer deposition of extracellular matrix components.” Biomaterials, 27 (2006) 1479. Full Text

18.  Cheng J, Teply BA, Jeong SY, Yim CH, Ho D, Sherifi I, Jon S, Farokhzad OC, Khademhosseini A and Langer RS. “Magnetically responsive polymeric microparticles for oral delivery of protein drugs.” Pharm Res, 23 (2006) 557. Full Text

17.  Farokhzad OC and Langer R. “Nanomedicine: developing smarter therapeutic and diagnostic modalities.” Adv Drug Deliv Rev, 58 (2006) 1456. Full Text

16.  Bagalkot V, Farokhzad OC, Langer R and Jon S. “An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform.” Angew Chem Int Ed Engl, 45 (2006) 8149. Full Text

15.  Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP and Langer R. “Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.” Proc Natl Acad Sci U S A, 103 (2006) 6315. Full Text

14.  Farokhzad OC, Khademhosseini A, Jon S, Hermmann A, Cheng J, Chin C, Kiselyuk A, Teply B, Eng G and Langer R. “Microfluidic system for studying the interaction of nanoparticles and microparticles with cells.” Anal Chem, 77 (2005) 5453. Full Text

13.  Khademhosseini A, Yeh J, Eng G, Karp J, Kaji H, Borenstein J, Farokhzad OC and Langer R. “Cell docking inside microwells within reversibly sealed microfluidic channels for fabricating multiphenotype cell arrays.” Lab Chip, 5 (2005) 1380. Full Text

12.  Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA and Langer R. “Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.” Cancer Res, 64 (2004) 7668. Full Text

11.  Nicolaou F, Teodoridis JM, Park H, Georgakis A, Farokhzad OC, Böttinger EP, Da Silva N, Rousselot P, Chomienne C, Ferenczi K, Arnaout MA and Shelley CS. “CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and j.” Blood, 101 (2003) 4033. Full Text

10.  Shelley CS, Teodoridis JM, Park H, Farokhzad OC, Böttinger EP and Arnaout MA. “During differentiation of the monocytic cell line U937, Pur alpha mediates induction of the CD11c beta 2 integrin gene promoter.” J Immunol, 168 (2002) 3887. Full Text

9.    Song JC, Hanson CM, Tsai V, Farokhzad OC, Lotz M and Matthews JB. “Regulation of epithelial transport and barrier function by distinct protein kinase C isoforms.” Am J Physiol Cell Physiol, 281 (2001) C649. Full Text

8.    Farokhzad OC, Teodoridis JM, Park H, Arnaout MA and Shelley CS. “CD43 gene expression is mediated by a nuclear factor which binds pyrimidine-rich single-stranded DNA.” Nucleic Acids Res, 28 (2000) 2256-67. Full Text

7.    Song JC, Hrnjez BJ, Farokhzad OC and Matthews JB. “PKC-epsilon regulates basolateral endocytosis in human T84 intestinal epithelia: role of F-actin and MARCKS.” Am J Physiol, 277 (1999) C1239. Full Text

6.    Farokhzad OC, Sagar GD, Mun EC, Sicklick JK, Lotz M, Smith JA, Song JC, O’Brien TC, Sharma CP, Kinane TB, Hodin RA and Matthews JB. “Protein kinase C activation downregulates the expression and function of the basolateral Na+/K+/2Cl(-) cotransporter.” J Cell Physiol, 181 (1999) 489. Full Text

5.    Farokhzad OC, Mun EC, Sicklick JK, Smith JA and Matthews JB. “Effects of bryostatin 1, a novel anticancer agent, on intestinal transport and barrier function: role of protein kinase C.” Surgery, 124 (1998) 380. Full Text

4.    Mun EC, Mayol JM, Riegler M, O’Brien TC, Farokhzad OC, Song JC, Pothoulakis C, Hrnjez BJ and Matthews JB. ” Levamisole inhibits intestinal Cl- secretion via basolateral K+ channel blockade.” Gastroenterology, 114 (1998) 1257. Full Text

3.    Farokhzad OC, Shelley CS and Arnaout MA. “Induction of the CD11b gene during activation of the monocytic cell line U937 requires a novel nuclear factor MS-2.” J Immunol, 157 (1996) 5597. Full Text

2.    Böttinger EP, Shelley CS, Farokhzad OC and Arnaout MA. ” The human beta 2 integrin CD18 promoter consists of two inverted Ets cis elements.” Mol Cell Biol, 16 (1994) 2604. Full Text

1. Shelley CS, Farokhzad OC and Arnaout MA. ” Identification of cell-specific and developmentally regulated nuclear factors that direct myeloid and lymphoid expression of the CD11a gene.” Proc Natl Acad Sci U S A, 90 (1993) 5364. Full Text